Ocular Therapeutix™ to Present at September Retina Meetings
Ocular Therapeutix (NASDAQ: OCUL) announces multiple presentations at four major retina meetings in Portugal and Spain this September. The presentations focus on their innovative therapies for retinal diseases, particularly the axitinib hydrogel implant (OTX-TKI) for treating neovascular age-related macular degeneration (AMD) and diabetic retinopathy.
Key presentations include:
- 52-week results of OTX-TKI in AMD patients at The Retina Society meeting
- One-year results of OTX-TKI in diabetic retinopathy from the HELIOS Phase 1 trial
- Panel discussions on novel drug delivery approaches for posterior segment diseases
- 48-week safety and efficacy results from the HELIOS trial for non-proliferative diabetic retinopathy
These presentations highlight Ocular's transformation into a retina-focused company and its efforts to change the future paradigm for managing retinal vascular diseases.
Ocular Therapeutix (NASDAQ: OCUL) annuncia numerose presentazioni in quattro importanti congressi sulla retina in Portogallo e Spagna questo settembre. Le presentazioni si concentrano sulle loro innovative terapie per le malattie retinali, in particolare l'impianto di idrogel di axitinib (OTX-TKI) per il trattamento della degenerazione maculare legata all'età (AMD) e della retinopatia diabetica.
Le presentazioni chiave includono:
- Risultati a 52 settimane di OTX-TKI nei pazienti con AMD al congresso della Retina Society
- Risultati a un anno di OTX-TKI nella retinopatia diabetica dallo studio HELIOS di fase 1
- Discussioni in panel su approcci innovativi nella somministrazione di farmaci per le malattie del segmento posteriore
- Risultati di sicurezza ed efficacia a 48 settimane dallo studio HELIOS per la retinopatia diabetica non proliferativa
Queste presentazioni evidenziano la trasformazione di Ocular in un'azienda focalizzata sulla retina e i suoi sforzi per cambiare il paradigma futuro nella gestione delle malattie vascolari retiniche.
Ocular Therapeutix (NASDAQ: OCUL) anuncia múltiples presentaciones en cuatro importantes congresos sobre retina en Portugal y España este septiembre. Las presentaciones se centran en sus terapias innovadoras para enfermedades retinianas, en particular en el implante de hidrogel de axitinib (OTX-TKI) para el tratamiento de la degeneración macular neovascular relacionada con la edad (AMD) y la retinopatía diabética.
Las presentaciones clave incluyen:
- Resultados a 52 semanas de OTX-TKI en pacientes con AMD en la reunión de la Retina Society
- Resultados a un año de OTX-TKI en retinopatía diabética del ensayo HELIOS de fase 1
- Discusiones en panel sobre enfoques novedosos de administración de fármacos para enfermedades del segmento posterior
- Resultados de seguridad y eficacia a 48 semanas del ensayo HELIOS para la retinopatía diabética no proliferativa
Estas presentaciones destacan la transformación de Ocular en una empresa centrada en la retina y sus esfuerzos para cambiar el paradigma futuro en el manejo de enfermedades vasculares retinianas.
Ocular Therapeutix (NASDAQ: OCUL)은 이 9월 포르투갈과 스페인에서 열리는 네 개의 주요 망막 회의에서 여러 발표를 한다고 발표했습니다. 발표는 망막 질환에 대한 혁신적인 치료법, 특히 악시티닙 하이드로겔 임플란트(OTX-TKI)를 통한 신생혈관성 노인성 황반변성(AMD) 및 당뇨병성 망막병증 치료에 초점을 맞추고 있습니다.
주요 발표 내용은 다음과 같습니다:
- 망막 사회 회의에서 AMD 환자에 대한 OTX-TKI의 52주 결과
- 1상 HELIOS 시험에서 당뇨병성 망막병증에 대한 OTX-TKI의 1년 결과
- 후방 분절 질환에 대한 새로운 약물 전달 접근법에 관한 패널 토론
- 비증식성 당뇨병성 망막병증에 대한 HELIOS 시험의 48주 안전성 및 유효성 결과
이러한 발표는 Ocular가 망막 중심 회사로 변화하는 모습을 강조하며, 망막 혈관 질환 치료의 미래 패러다임을 변화시키기 위한 노력을 보여줍니다.
Ocular Therapeutix (NASDAQ: OCUL) annonce plusieurs présentations lors de quatre grandes conférences sur la rétine au Portugal et en Espagne ce mois de septembre. Les présentations portent sur leurs thérapies innovantes pour les maladies rétiniennes, en particulier l'implant d'hydrogel d'axitinib (OTX-TKI) pour le traitement de la dégénérescence maculaire néovasculaire liée à l'âge (AMD) et de la rétinopathie diabétique.
Les présentations clés incluent :
- Résultats à 52 semaines de l'OTX-TKI chez des patients atteints de AMD lors de la réunion de la Retina Society
- Résultats à un an de l'OTX-TKI pour la rétinopathie diabétique issus de l'essai HELIOS de phase 1
- Discussions en panel sur de nouvelles approches de délivrance de médicaments pour les maladies du segment postérieur
- Résultats de sécurité et d'efficacité à 48 semaines de l'essai HELIOS pour la rétinopathie diabétique non proliférative
Ces présentations soulignent la transformation d'Ocular en une entreprise axée sur la rétine et ses efforts pour changer le paradigme futur de la gestion des maladies vasculaires rétiniennes.
Ocular Therapeutix (NASDAQ: OCUL) kündigt mehrere Präsentationen auf vier bedeutenden Netzhautkonferenzen in Portugal und Spanien diesen September an. Die Präsentationen konzentrieren sich auf ihre innovativen Therapien für Netzhauterkrankungen, insbesondere das Axitinib-Hydrogel-Implantat (OTX-TKI) zur Behandlung der neovaskulären altersbedingten Makuladegeneration (AMD) und der diabetischen Retinopathie.
Wichtige Präsentationen umfassen:
- 52-Wochen-Ergebnisse von OTX-TKI bei AMD-Patienten auf der Tagung der Retina Society
- Ein-Jahres-Ergebnisse von OTX-TKI bei diabetischer Retinopathie aus der HELIOS-Phase-1-Studie
- Paneldiskussionen über neuartige Arzneimittelabgabeansätze für Erkrankungen des hinteren Segments
- 48-Wochen-Sicherheits- und Wirksamkeitsergebnisse aus der HELIOS-Studie bei nicht-proliferativer diabetischer Retinopathie
Diese Präsentationen heben die Transformation von Ocular zu einem auf die Retina fokussierten Unternehmen hervor und zeigen die Bemühungen, das zukünftige Paradigma für das Management von retinalen Gefäßerkrankungen zu verändern.
- None.
- None.
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced multiple presentations across four retina meetings being held in Portugal and Spain in September 2024.
Presentation Details (all times CEST):
The Retina Society 57th Annual Scientific Meeting: September 11-15, Lisbon, Portugal
- Oral Presentation: 52-week Rescue-Free Subjects Treated with Axitinib Hydrogel Implant (OTX-TKI) in the US Phase 1 Clinical Trial for Neovascular Age-Related Macular Degeneration
Session: Age Related Macular Degeneration III
Presentation Date/Time: Friday, September 13, 8:48 AM – 8:55 AM
Presenter: Andrew A. Moshfeghi, MD, MBA
- Oral Presentation: Safety and Efficacy of OTX-TKI in Moderately Severe to Severe NPDR: One Year Results from the HELIOS Phase 1 Trial (Late Breaking Presentation)
Session: Diabetic Retinopathy II
Presentation Date/Time: Saturday, September 14, 2024, 12:39 PM – 12:46 PM
Presenter: Dennis M. Marcus, MD
Ophthalmology Futures Forums (OFF) Retina Forum 2024: September 18, Barcelona, Spain
- Panel Title: Tyrosine Kinase Inhibitors and Other Novel Mechanisms for the Treatment of Neovascular AMD: Is There Unmet Need?
Session: Panel 1
Panel Date/Time: Wednesday, September 18, 10:00 AM – 10:30 AM
Ocular Therapeutix Panelist: Nadia K. Waheed, MD, MPH, Chief Medical Officer
- Panel Title: The Impact of Extended Duration with Injections on Novel Drug Delivery Approaches for Posterior Segment Diseases
Session: Panel 2
Panel Date/Time: Wednesday, September 18, 10:30 AM – 11:00 AM
Ocular Therapeutix Panelist: Peter K. Kaiser, MD, Chief Development Officer
- Company Presentation: Ocular Therapeutix: Transformation into a Retina-focused Company
Session: Company Presentations 2
Session Date/Time: Wednesday, September 18, 4:00 PM – 4:40 PM
Presenter: Peter K. Kaiser, MD, Chief Development Officer
EURETINA Innovation Spotlight (EIS): September 18, Barcelona, Spain
- Company Presentation: Changing the Future Paradigm for the Management of Retinal Vascular Diseases
Session: VEGF Related and Other Retinal Indications (Session 2)
Presentation Date/Time: Wednesday, September 18, 2:05 PM – 2:10 PM
Presenter: Nadia K. Waheed, MD, MPH, Chief Medical Officer
24th EURETINA Congress (EURETINA 2024): September 19-22, Barcelona, Spain
- Oral Presentation: 48-Week Safety and Efficacy Results from the Phase 1 HELIOS trial of Sustained-Release Axitinib Implant (OTX-TKI) for Non-Proliferative Diabetic Retinopathy
Session: Results of Clinical Trials and Late Breaking Session (Session 6)
Presentation Date/Time: Friday, September 20, 12:35 PM – 12:40 PM
Presenter: Veeral S. Sheth, MD, MBA, FACS, FASRS
- Audio Presentation: US Phase 1 Clinical Trial of Sustained-Release Axitinib Hydrogel Implant (AXPAXLI) in Subjects with Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Data
Date/Time: Available on terminals throughout the meeting
Presenter: Jordan M. Graff, MD, FACS
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
What is Ocular Therapeutix presenting at the September 2024 retina meetings?
Where are the retina meetings featuring Ocular Therapeutix presentations being held in September 2024?
What is the HELIOS Phase 1 trial that Ocular Therapeutix is presenting results from?
How is Ocular Therapeutix positioning itself in the retina treatment market?
